Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

BACKGROUND: This post-hoc analysis of the DELIGHT trial assessed effects of the SGLT2 inhibitor dapagliflozin on iron metabolism and markers of inflammation. METHODS: Patients with type 2 diabetes and albuminuria were randomized to dapagliflozin, dapagliflozin and saxagliptin, or placebo. We measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Koshino, Akihiko, Neuen, Brendon L., Jongs, Niels, Pollock, Carol, Greasley, Peter J., Andersson, Eva-Marie, Hammarstedt, Ann, Karlsson, Cecilia, Langkilde, Anna Maria, Wada, Takashi, Heerspink, Hiddo J.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685512/
https://www.ncbi.nlm.nih.gov/pubmed/38017482
http://dx.doi.org/10.1186/s12933-023-02027-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685512/
https://www.ncbi.nlm.nih.gov/pubmed/38017482
http://dx.doi.org/10.1186/s12933-023-02027-8

Ejemplares similares